Skip to main content

Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
bamlanivimab
bamlanivimab etesevimab
casirivimab imdevimab
sotrovimab
Health Outcome(s)
anaphylaxis
hospitalization
Description

This analysis is part of the ongoing effort to monitor the utilization of outpatient COVID-19 treatment under emergency use authorization (EUA). In this request we examined use of monoclonal antibodies (mAb) in the Rapid COVID Sentinel Distributed Database (SDD). This request had three Aims:

  • Aim 1: Characterize mAb users, mAb non-users, and COVID-19 patients
  • Aim 2: Estimate rates of hospitalization following outpatient mAb use
  • Aim 3: Estimate rates of anaphylaxis following mAb use

The study period for Aims 1 and 2 includes data from November 9, 2020 up to June 30, 2021. The study period for Aim 3 includes data from November 9, 2020 up to September 30, 2021 (most recent available data). We distributed this request to six Sentinel Rapid COVID Data Partners on December 27, 2021.

Deliverables (1)
Sentinel Modular Program Report: Hospitalization and Anaphylaxis Following Monoclonal Antibodies Use in Patients with COIVID-19: A Descriptive Analysis